Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$52.78 USD

52.78
879,596

+2.31 (4.58%)

Updated Jan 27, 2023 04:00 PM ET

After-Market: $52.70 -0.08 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.28%
2Buy17.83%
3Hold9.19%
4Sell5.00%
5Strong Sell2.16%
S&P50010.51%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 249)

Industry: Medical - Biomedical and Genetics

Trades from $1

Zacks News

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $50.47, moving -0.55% from the previous trading session.

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.96, moving +1.25% from the previous trading session.

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.94, marking a +0.56% move from the previous day.

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $46.68, moving -1.12% from the previous trading session.

Vertex (VRTX) to Start Clinical Study on mRNA-based CF Therapy

Following clearance of the IND application by the FDA, Vertex (VRTX) intends to start a clinical study evaluating a single ascending dose of VX-522 in cystic fibrosis patients in the coming weeks.

Why Is CRISPR Therapeutics AG (CRSP) Up 0.2% Since Last Earnings Report?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates

CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 2.61% and 97.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance

Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading.

Earnings Preview: Exact Sciences (EXAS) Q3 Earnings Expected to Decline

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?

CRISPR Therapeutics AG (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?

On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

CRSIPR Therapeutics (CRSP) is expected to update its pipeline candidates, specifically exa-cel, its lead candidate, in its third-quarter earnings.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $50.84, marking a -0.88% move from the previous day.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $58.06, marking a -0.77% move from the previous day.

Here's Why You Should Invest in Vertex (VRTX) Stock Now

Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.

The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.

Indrajit Bandyopadhyay headshot

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, which have the potential to gain from their promising gene therapy pipeline candidates.

bluebird's (BLUE) Gene Therapy Approvals to Drive the Top Line

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, are expected to drive the top line.

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $65.35, marking a +1.33% move from the previous day.

Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy

Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $70.13, moving +1.9% from the previous trading session.

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $66.27 in the latest trading session, marking a +1.94% move from the prior day.

CRISPR Therapeutics AG (CRSP) Down 16.5% Since Last Earnings Report: Can It Rebound?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRISPR Therapeutics' (CRSP) Pipeline Development Fuels Growth

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.